Search
A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.
Read moreFirst randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreThe European Union must deliver funding for research of blood disorders
At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.
Read moreTraining vital for new era of patient-centric healthcare
Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…
Read moreEHA - Access to Medicine
By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW
Read moreMajor research funding calls are out now
First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.
Read moreThe International Society on Thrombosis and Haemostasis (ISTH) Hosts its Second Advanced Training Course on Thrombosis and Haemostasis on March 13-16, 2014
The Second Advance Training Course is a follow-up to the successful inaugural course organized in 2011 and attended by 200 professionals. Course speakers include nine international and regional experts in the field of thrombosis and haemostasis.
Read morePosition of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.
Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013
In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.
Read moreExciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013
Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.
Read more